OncLive.com· @OncLive · X·· 14 小时前评分70
正文 · 机器翻译
📈 在HER2+早期乳腺癌中，新辅助T-DXd后序贯THP在MRI上比ddAC-THP产生了更快且更深度的肿瘤应答，但DESTINY-Breast11分析显示，MRI应答并不能可靠预测pCR。@myESMO #ESMO2026 #bcsm #oncology
阅读更多：https://www.onclive.com/view/t-dxd-followed-by-thp-elicits-deep-mri-responses-in-her2-early-breast-cancer
171 浏览 · 1 赞 · 2 转发 · 0 回复
会议摘要
543RO按 Rapid oral: Breast cancer, early stage 对上
DESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (
https://esmocongress.esmo.org来源：OncLive.com · x.com